Equity Agreement With LLC Gives MediciNova Potential To Move Two Lead Programs Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
A $20 million common stock purchase agreement with Aspire Capital provides MediciNova some breathing room as it attempts to negotiate partnerships around a pair of mid-stage small-molecule candidates.
You may also be interested in...
Bad Haircuts: 2005's Biotech IPOs--Getting Out at Any Price?
The haircuts suffered by 2005's biotech IPOs are further proof that while the appetite for biotech offerings exists, public investors are demanding a better likelihood of post-market upside.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.